November 1, 2023
National Institute on Drug Abuse (NIDA)
This Notice informs potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in the notice of funding opportunity (NOFO) PAR-23-309, "Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional). "
The following sections of PAR-23-309 are updated as follows, shown in bold italics
National Institute on Minority Health and Health Disparities (NIMHD)
National Eye Institute (NEI)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Nursing Research (NINR)
National Cancer Institute (NCI)
All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.
Sexual and Gender Minority Research Office (SGMRO)
Office of Behavioral and Social Sciences Research (OBSSR)
Assistance Listing Number(s)
93.307, 93.173, 93.865, 93.286, 93.361, 93.867, 93.273, 93.866, 93.399, 93.846, 93.853, 93.279
The following content has been added:
National Institute on Drug Abuse (NIDA)
The mission of NIDA is to advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health. NIDA is interested in supporting research relevant to advancing the understanding of the effects of substance use among people living with disabilities and experiencing health disparities. This includes the identification and development of innovative strategies, prevention, and intervention methods, as well as policy changes to reduce negative effects of substance use among this population, specifically among racial and ethnic minorities, sexual and gender minorities, and other underserved populations. Priority areas include but are not limited to research on the following:
The following contacts have been added:
Scientific/Research Contact(s)
Sheba K. Dunston, EdD
National Institute on Drug Abuse (NIDA)
Phone: 301-402-1526
Email: Sheba.Dunston@nih.gov
Financial/Grants Management Contact(s)
Christina Rinaldi
National Institute on Drug Abuse (NIDA)
Phone: 301-827-0937
Email: christina.rinaldi@nih.gov
All other aspects of the NOFO remain the same.
Sheba K. Dunston, EdD
National Institute on Drug Abuse (NIDA)
Phone: 301-402-1526
Email: Sheba.Dunston@nih.gov